Did Tempus AI beat or miss consensus estimates last quarter?

What were the key takeaways from Tempus AI's earnings call?

What does Tempus AI do and what are its main business segments?

What factors drove the changes in Tempus AI's revenue and profit?

What is Tempus AI's gross profit margin?

What were the key takeaways from Tempus AI’s earnings call?

What is Tempus AI's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Tempus AI year over year?

- **Record Growth**: Oncology (+27%) and Hereditary (+37%) testing volumes driven by efficient sales force and comprehensive portfolio. Data licensing bookings of $150 million highlight strong demand for differentiated analytics.
- **Profitability Milestone**: First-quarter positive EBITDA ($4 million) achieved despite Paige acquisition costs; full-year EBITDA expected to be slightly positive.
- **Strategic Expansion**: Paige acquisition integrates digital pathology with genomics, enabling faster, more accurate diagnostics. Regulatory filings for xF and xR position for long-term reimbursement upside.
- **Sustainable Growth**: 25%+ annual growth target for Genomics and Insights businesses supported by cost control and multiyear data licensing contracts.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Genomics volume grew 3% overall, with Oncology up 27% and Hereditary up 37%. Data licensing bookings reached $150 million, driving Insights business growth of 38%. Achieved first-time positive adjusted EBITDA of $4 million (excluding Paige acquisition costs), with full-year EBITDA expected to be slightly positive.
- **Strategic Initiatives**: MRD reimbursement on track; liquid biopsy xF regulatory filing planned for late 2025. Paige acquisition integrates digital pathology with genomics to enhance diagnostic accuracy and speed.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income of $420 million; Non-GAAP EPS of $1.08 exceeded expectations. Adjusted EBITDA turned positive due to cost control and operational efficiency. Paige acquisition added $2 million in quarterly expenses but did not impede EBITDA positivity.
- **Guidance**: Full-year adjusted EBITDA expected to be slightly positive, despite Paige-related drag. Reimbursement for xF and xR expected to provide long-term margin upside, with current average reimbursement at $1,600 per test.

**【Q&A Key Highlights】**
- **MRD Testing**: 27% unit growth in Oncology driven by comprehensive portfolio; Paige's tumor-naive assays for CRC and lung cancer expected to yield data in 2026. No plans for aggressive market expansion post-reimbursement.
- **Reimbursement & Pricing**: xF FDA submission in Q4 2025; xR PMA submission to follow. ADLT status for FDA-approved tests could increase Medicare list prices, closing gap with peers.
- **Data Licensing**: $150 million in multiyear bookings reflect differentiated data asset; annual contract value >$350 million. Growth driven by software tools and library licensing.
- **Hereditary Business**: Low double-digit industry growth baseline; Ambry expects low to mid-20s growth, with 50% of Q3 gain from share capture. Rare disease testing ASPs higher but still small-scale.
- **Paige Synergies**: Digital pathology algorithms enhance sequencing by predicting mutations when NGS fails; multimodal approach to patient data expected to scale rapidly with reimbursement.

Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript

Genomics

Data and Services

TEM

TEM fundamentals

You can ask Aime